FDx Advisors, Inc.
- SEC CIK
- 0001566601
- Latest filing
- Aug 4, 2026
ZTS holding history
Zoetis Inc. in every 13F filed by FDx Advisors, Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ZTS overviewAll 13F holders of ZTSFull Q2 2026 holdings
- Shares (Q4 2025)
- 0
- Sold out in Q4 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2025 | 0 | $0 | 0.0% | −1,917−100.0% | Sold out | Holders |
| Q3 2025 | 1,917 | $276.0K | 0.1% | +293+18.0% | Added | Holders |
| Q2 2025 | 1,624 | $253.0K | 0.1% | +21+1.3% | Added | Holders |
| Q1 2025 | 1,603 | $264.0K | 0.1% | −79−4.7% | Reduced | Holders |
| Q4 2024 | 1,682 | $274.0K | 0.1% | +241+16.7% | Added | Holders |
| Q3 2024 | 1,441 | $282.0K | 0.1% | +138+10.6% | Added | Holders |
| Q2 2024 | 1,303 | $226.0K | 0.1% | −16,575−92.7% | Reduced | Holders |
| Q1 2024 | 17,878 | $3.02M | 0.5% | +337+1.9% | Added | Holders |
| Q4 2023 | 17,541 | $3.46M | 0.3% | −2,765−13.6% | Reduced | Holders |
| Q3 2023 | 20,306 | $3.53M | 0.3% | −11,237−35.6% | Reduced | Holders |
| Q2 2023 | 31,543 | $5.43M | 0.3% | −108,323−77.4% | Reduced | Holders |
| Q1 2023 | 139,866 | $20.5M | 0.9% | 00.0% | Unchanged | Holders |
| Q4 2022 | 139,866 | $20.5M | 0.9% | −1,070−0.8% | Reduced | Holders |
| Q3 2022 | 140,936 | $20.9M | 0.9% | −36,847−20.7% | Reduced | Holders |
| Q2 2022 | 177,783 | $30.6M | 1.1% | −62,037−25.9% | Reduced | Holders |
| Q1 2022 | 239,820 | $45.2M | 1.5% | −32,939−12.1% | Reduced | Holders |
| Q4 2021 | 272,759 | $66.6M | 1.8% | +14,226+5.5% | Added | Holders |
| Q3 2021 | 258,533 | $50.2M | 1.6% | −35,504−12.1% | Reduced | Holders |
| Q2 2021 | 294,037 | $54.8M | 1.8% | +15,568+5.6% | Added | Holders |
| Q1 2021 | 278,469 | $43.9M | 1.7% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.